Search

Chairs and Members

The EHA SWG commenced in 2020, but initial work was delayed due to the COVID-19 pandemic. We therefore started in 2021, in preparation for a (successful) SWG meeting in 2022.

Read more

European Research Initiative on CLL (ERIC)

ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:

Research in all aspects of chronic lymphocytic leukemia and related diseases.

Read more

Transfusion

The aim of this SWG is to strengthen and invigorate European research in transfusion, to foster new networks and collaborations, with the ultimate goal of optomisingtransfusion practice in Europe based on scientific evidence.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA returns to Cairo with the Highlights of the 24th EHA Congress

The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology…

Read more

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more